A prospective multicenter cohort study reports that lecanemab treatment in a Chinese Alzheimer’s population was associated with cognitive stability and amyloid clearance over 13 months, alongside an acceptable safety profile. The study, published in the Journal of Neurology, enrolled 122 treated patients across nine medical centers in Southwest China. Researchers tracked objective clinical assessments, caregiver-reported outcomes, safety events, and imaging endpoints including amyloid-beta PET and CT. Using linear mixed-effects models across 222 follow-up visits, the treated cohort showed generally stable cognition with modestly favorable changes at select time points. When benchmarked against propensity score-matched local natural-history controls and an external cohort from the Alzheimer’s Disease Neuroimaging Initiative, patients receiving lecanemab had more favorable longitudinal cognitive trajectories. The data aims to address uncertainty around longer-term effectiveness and predictors of response in a specific real-world population.
Get the Daily Brief